Labeling MatB. Labeling and purification are described for the final sensor variant RpMatB ((His 6 /C106A/R286C/Q457C/K488A)RpMatB). Any differences from this procedure for other RpMatB variants are described after.
Dithiothreitol was removed from ~40 mg of RpMatB using a PD10 desalting column (GE Healthcare) pre-equilibrated with Buffer L (30 mM Tris.HCl pH 7.5, 100 mM NaCl) at 20 °C. 50 µM protein was incubated at 20 °C with 225 µM 5-IATR (AnaSpec) in Buffer L using an end-over-end mixer for 90 min. Then 2 mM sodium-2-mercaptoethanesulfonate was added and incubation continued for 15 min. After centrifugation at 3500 rpm for 15 min at 4 °C (Heraeus Biofuge), the supernatant was filtered through a 0.2 µm syringe filter (Acrodisc Syringe Filter with HT Tuffryn Membrane, Pall Life Sciences) and loaded onto a PD10 desalting column, equilibrated with Buffer Q1 (30 mM Tris.HCl pH 8.0, 25 mM NaCl) at ~20 °C to remove free label.
The final biosensor was further purified via ion exchange chromatography at 4 °C using a 1 ml HiTrap Q HP column (GE Healthcare), equilibrated in Buffer Q1 at 1 ml min -1 . After sample loading, the column was washed with 90 ml Buffer Q1. The protein was eluted using a gradient from 100% Buffer Q1 to 50% Buffer Q1 and 50% Buffer Q2 (30 mM Tris.HCl pH 8.0, 1 M NaCl) over 25 ml followed by a gradient from 50% Buffer Q1 and 50% Buffer Q2 to 100% Buffer Q2 over 10 ml. Rho-MatB eluted as two overlapping peaks with identical mass and fluorescence properties. Both peaks were pooled and concentrated to ~5 mg ml -1 using a concentrator (Amicon Ultra-4 10 kDa cut off, Millipore).
While screening for a fluorescence change upon ATP binding, labeling was performed on a scale of ~2 mg of protein. RpMatB variants (100 µM) were incubated at 20 °C with 2-fold excess MDCC over RpMatB for 35 min, or with 2-fold excess IDCC for 120 min, or with 4-fold excess 5-IATR or 6-IATR for 90 min. During screening, the labeled RpMatB variants were purified only using a PD10 desalting column.
The labeled protein concentrations were determined using the following extinction coefficients: RpMatB: ε 280 4 . The protein was drop-frozen in liquid nitrogen and stored at -80 °C. Labeling yields were up to 35%.
Using mass spectrometry, unlabeled RpMatB ((His 6 /C106A/R286C/Q457C/K488A)RpMatB) had a mass of 57335.9 Da. The theoretical molecular weight is 57324.2 Da, assuming loss of the N-terminal methionine. Presumably, other post-translational modifications, such as partial oxidation of surface-accessible methionines, occur 5 . The final biosensor, Rho-MatB ((5-ATR)2-(His 6 /C106A/R286C/Q457C/K488A)RpMatB), had a mass of 58216.4 Da, conforming to the theoretical molecular weight of the RpMatB protein with two 5-ATRs attached (57335.9 + 2 × 441.5).
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Supporting Method: Global fitting of association time courses
The global best-fit values and confidence intervals for rate constants that describe the binding of ATP to RhoMatB, using the conformational selection scheme ( Figure 5A ). A set of data with ATP in excess and one with protein in excess were fit using KinTek Global Kinetic Explorer (v 4.0) 6, 7 . Data points with t < 0.002 s in all data sets were removed as they were within the dead time of the stopped flow instrument. An initial incubation step was included in the calculations to enable the two apo conformations, Rho-MatB 1 and RhoMatB 2 , to equilibrate before addition of ATP.
The fluorescence change in the fitting was described by a differential fluorescence factor, which was the difference between the fluorescence of apoprotein and ATP-bound Rho-MatB to relate fluorescence to concentration. Experimental traces with excess protein and with excess ATP were from different experimental protocols, requiring different instrumental settings and resulting in different absolute fluorescence values. Therefore, different fluorescence factors were used for the two types of experiments. The starting fluorescence values (offsets) were treated as adjustable model parameters.
A one-dimensional FitSpace calculation 6 was used to determine the range over which each rate constant can vary, while still allowing an acceptably good fit within a Chi 2 threshold of 1.2-fold of the minimum value. The fluorescence enhancement factor was allowed to vary along with rate constants, but offset values were fixed during this calculation. Table S1 : Fluorescence changes for binding of ATP and ADP to fluorophore-RpMatB adducts. Cysteine mutations were introduced into (His 6 /C106A/K488A)RpMatB. Diethylaminocoumarin, using MDCC or IDCC, or tetramethylrhodamine, using 5-IATR or 6-IATR, were covalently linked to the protein. Data are from a survey without complete optimization of the labeling and purification. The fluorescence changes (F + /F -) upon ligand binding were obtained by excitation at 553 nm and emission at 577 nm for tetramethylrhodamine and excitation at 431 nm and emission at 470 nm for diethylaminocoumarin at 20 °C in 50 mM Tris.HCl pH 7.5, 100 mM NaCl, 10 mM MgCl 2 , 0.3 mg ml -1 bovine serum albumin using 1 µM RpMatB adduct with or without saturating ATP.
Cysteine Mutations
Labeling reagent
a Values were obtained for the fluorescence ratio with ADP (0.5), the dissociation constant for ATP (0.6 μM) and for ADP (98 μM), as described in the text for Rho-MatB. Values were obtained for the fluorescence ratio with ADP (1.9), the dissociation constant for ATP (2.7μM) and for ADP (293 μM), as described in the text for Rho-MatB. The structural relationship between apo and holo structures was determined, based on the root mean square deviation (RMSD) of the α-carbon atoms of aligned residues using SuperPose 9 . The table shows that not only RpMatB but also other ANL superfamily members undergo a conformational change after ATP (or analogue) binding, although in two cases, the apo crystals had multiple structures, including one similar to the closed (ligand-bound) structure, based on the low RMSD.
The relative interdomain orientations were visually inspected for the placement of the C-terminal domain with respect to its N-terminal domain after superposing the N-terminal domains. For the holo molecules, 9 out of 11 structures had conserved interdomain geometry. In contrast, the superposition of the apo molecules showed large variations in the positioning of the C-terminal domain relative to the N-terminal domain.
a Ratio of the average B-factor for the C-terminal domain using all atoms of the C-terminal domain and that of the N-terminal domain. b These crystals contained molecules that had two different conformations. Both conformations were used in the analysis. c Only partially resolved C-terminal domain. Figure 5A and Figure S3 shows the fitted curves. Confidence ranges were obtained for rate constants with Chi 2 being within 1. It also assumed Rho-MatB⋅ATP has 2-fold higher fluorescence than the apo protein, to give relative amplitudes of the two phases as observed experimentally. For all curves there was no further attempt to obtain amplitudes that exactly matched experimental data. Particularly with excess Rho-MatB, these amplitudes are affected by background levels and optics. Figure  5A ). Further information is in the Supporting Method. The fitting procedure included a preincubation to enable the two apo conformations, Rho-MatB 1 and Rho-MatB 2 , to equilibrate before addition of ATP. Like the simulations in Figure S2 , it was assumed that the fluorescence of Rho-MatB 1 equals that of Rho-MatB 2 . Note this aspect was not well tested by this fitting, as small difference in the intensities will be reflected only in the relative amplitudes of the two phases. The amplitudes of the rapid phase are not accurate due to their small size (excess Rho-MatB) and loss of signal during the instrument dead time (excess ATP). Experimental traces are solid lines, fitted curves are dashed. The concentrations of the species in excess are shown for each curve. Traces at high [Rho-MatB] were excluded as the high concentrations affected the fluorescence amplitudes due to the inner filter effect. The resulting rate constants and statistics are in Table S5 .
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Figure S4: Oligomerization of RpMatB and Rho-MatB, analyzed by SEC-MALLS. The solution molecular weight was analyzed using size exclusion chromatography coupled to multi-angle laser light scattering (SEC-MALLS). Rho-MatB (blue) and (His 6 /C106A/R286C/Q457C/K488A)RpMatB (red) were analyzed by SEC-MALLS in the absence (A) or presence of MgATP (B). The differential refractive index (to show the protein peaks) and the molar mass distributions were plotted against time.
~15 µM Rho-MatB or (His6/C106A/R286C/Q457C/K488A)RpMatB were applied in a volume of 100 µl to a Superdex 200 10/300 GL column (GE Healthcare) connected to a Jasco PU-1580 HPLC at a flow rate of 0.5 ml min -1 . The HPLC system was connected to a Dawn Heleos II light scattering instrument (Wyatt Technology) and Optilab T-rex differential refractometer (Wyatt Technology). The solution molecular weight was determined from the combined data from both detectors using the ASTRA software version 6.1.1.17 (Wyatt Technology) with the refractive index increment set to 0.1860 ml g -1 .
The analysis was at ~20 °C in 30 mM Tris.HCl pH 7.5, 100 mM NaCl, 3 mM NaN 3 with or without MgATP (5 mM MgCl 2 , 50 µM ATP). 
